Cover Image

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial

Saved in:
Bibliographic Details
Main Authors: Javle, Milind (Author) , Borbath, I. (Author) , Clarke, S. (Author) , Hitre, E. (Author) , Louvet, C. (Author) , Macarulla, T. (Author) , Oh, D. (Author) , Spratlin, J. (Author) , Valle, J. (Author) , Weiss, Karl Heinz (Author) , Berman, C. (Author) , Howland, M. (Author) , Ye, Y. (Author) , Cho, T. (Author) , Moran, S. (Author) , Abou-Alfa, G. (Author)
Format: Article (Journal) Conference Paper
Language:English
Published: 2019
In: Annals of oncology
Year: 2019, Volume: 30, Pages: iv62
ISSN:1569-8041
DOI:10.1093/annonc/mdz155.224
Online Access:Verlag, lizenzpflichtig: https://doi.org/10.1093/annonc/mdz155.224
Verlag, lizenzpflichtig: http://www.sciencedirect.com/science/article/pii/S0923753419307434
Get full text
Author Notes:M Javle, I Borbath, S Clarke, E Hitre, C Louvet, T Macarulla, D Oh, J Spratlin, J Valle, K Weiss, C Berman, M Howland, Y Ye, T Cho, S Moran, G Abou-Alfa
Description
Item Description:Poster
Conference abstract P-225
Gesehen am 03.07.2020
Physical Description:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdz155.224

Similar Items